التفاصيل البيبلوغرافية
| العنوان: |
Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma. |
| المؤلفون: |
Nolan, Ryan1, Holle, Lisa M.2 |
| المصدر: |
Drug Topics. Feb2021, Vol. 165 Issue 2, p32-32. 1p. |
| مصطلحات موضوعية: |
MULTIPLE myeloma, ANTIBODY-dependent cell cytotoxicity, BLOOD cell count, CD38 antigen, RITUXIMAB |
| مستخلص: |
The article offers information on the Belantamab Mafodotin-blmf for Relapsed or Refractory Multiple Myeloma. It discusses about the Belantamab mafodotin-blmf is a first-in-class, anti–B-cell maturation antigen immunoconjugate with afucosylated, humanized immunoglobulin G1 anti-BCMA monoclonal antibody conjugated by a protease-resistant maleimidocaproyl linker to a microtubule-disrupting agent, monomethyl auristatin F (MMAF). |
| قاعدة البيانات: |
Business Source Index |
Full Text Finder